Blog
Daily evidence-led peptide research, regulatory news, expert digest and explainers. Every claim sourced; no AI tells.
Page 9
Semaglutide Patches Need a Different Needle
New research shows dissolving microneedle patches need different needle designs for semaglutide than for small drugs.
Semaglutide Plus Niacin for Lung Fibrosis
A rat study paired semaglutide with niacin against lung scarring, targeting the NAD+/SIRT1-FOXO3a-Nrf2 pathway. Here is what it does and does not show.
Tirzepatide, GLP-1 Drugs, and Gum Disease
A large propensity-matched study links tirzepatide to lower periodontal disease risk than other GLP-1 drugs in type 2 diabetes.
New Model Explains Tirzepatide's Edge
A modeling study traces tirzepatide's fasting-glucose advantage over semaglutide to greater liver glucose suppression, not beta cells or extra weight loss.
How Trump's GLP-1 price plan works
The US GLP-1 price plan uses several payment channels, so cash offers, Medicare terms and a patient's final cost are not the same.
Adolescent Obesity Drugs: 2026 Review
A 2026 review finds the strongest adolescent obesity evidence for semaglutide, while tirzepatide and CagriSema still lack comparable data.
Can Retatrutide Be Compounded?
FDA says retatrutide cannot be compounded under federal law. Lilly's six lawsuits show why investigational status matters.
GLP-1 Drugs and Pulmonary Hypertension
GLP-1 drugs have an observational signal in pulmonary hypertension, but no trial yet shows that retatrutide or the class treats the condition.
What Lilly and Novo's Q2 Results Mean
Lilly beat expectations while Novo stumbled, but the quarter says more about GLP-1 market momentum than individual treatment choice.
Orforglipron: an oral GLP-1 option
Orforglipron is an oral GLP-1 receptor agonist for obesity. Here is what trial evidence shows, and what remains uncertain.
What retatrutide access can reveal
Lilly widened retatrutide compassionate access, but individual cases cannot replace randomized evidence on benefits, risks, or response.
Retatrutide expanded access explained
Lilly will review more requests for retatrutide expanded access, but the investigational obesity drug remains unapproved and tightly restricted.